Lapatinib Resistance in Patients With Breast Cancer
Public ClinicalTrials.gov record NCT00898573. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about cancer and the development of drug resistance in patients. PURPOSE: This research study is looking at lapatinib resistance in patients with breast cancer.
Study identification
- NCT ID
- NCT00898573
- Recruitment status
- Withdrawn
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- lapatinib ditosylate Drug
- fluorescence in situ hybridization Genetic
- gene expression analysis Genetic
- mutation analysis Genetic
- polymerase chain reaction Genetic
- reverse transcriptase-polymerase chain reaction Genetic
- cell sorting Other
- immunohistochemistry staining method Other
- laboratory biomarker analysis Other
Drug · Genetic · Other
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2008 (Type not available)
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Oct 2, 2015
Started 2008
United States locations
- U.S. sites
- 9
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Geauga Regional Hospital | Cleveland | Ohio | 44024 | — |
| Lake/University Ireland Cancer Center | Cleveland | Ohio | 44060 | — |
| Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center | Cleveland | Ohio | 44106-5065 | — |
| University Suburban Health Center | Cleveland | Ohio | 44121 | — |
| UHHS Chagrin Highlands Medical Center | Cleveland | Ohio | 44122 | — |
| Southwest General Health Center | Cleveland | Ohio | 44130 | — |
| UHHS Westlake Medical Center | Cleveland | Ohio | 44145 | — |
| Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center | Cleveland | Ohio | 44195 | — |
| Mercy Cancer Center at Mercy Medical Center | Cleveland | Ohio | 44708 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00898573, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 2, 2015 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00898573 live on ClinicalTrials.gov.